Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those ... Now, he’s a Mets’ batting ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

Ohio weight-loss clinics continue to be disciplined over alleged unsafe practices and false claims that they pass regulatory ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...